Harnessing RNAi nanomedicine for precision therapy

Abstract

Utilizing RNA interference as an innovative therapeutic strategy has an immense likelihood to generate novel
concepts in precision medicine. Several clinical trials are on the way with some positive initial results. Yet, targeting
of RNAi payloads such as small interfering RNAs (siRNAs), microRNA (miR) mimetic or anti-miR (antagomirs) into
specific cell types remains a challenge. Major attempts are done for developing nano-sized carriers that could
overcome systemic, local and cellular barriers. This progress report will focus on the recent advances in the RNAi
world, detailing strategies of systemic passive tissue targeting and active cellular targeting, which is often considered
as the holy grail of drug delivery.